However, with the introduction of novel therapies into the standard of care in the recent decade, such as second-generation proteasome inhibitors (carfilzomib, ixazomib), third-generation immunomodulatory drugs (pomalidomide), HDAC inhibitors (panobinostat), monoclonal antibodies (daratumumab, isatuximab, elotuzumab), and the BCL-2 inhibitor venetoclax, approximately 90% of myeloma patients have a considerable chance of reaching complete remission and measurable residual disease negativity [4,29,30]. The gene discussed is HDAC9; the disease is plasma cell myeloma.